Conclusion Of Non Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Doxylamine 6 96 Mg Pyridoxine 8 23 Mg Hvw Cariban

Deadline: 10 Nov 2026

Germany

Ref. No.: 10593052

EMD:Ref Document

Bid Value: Ref Document

198 Days Left

Pharmaceutical Contracts With Accession Option

Deadline: 01 Nov 2026

Germany

Ref. No.: 10589991

EMD:Ref Document

Bid Value: Ref Document

189 Days Left

Open House Biologics Discount Agreements 2024 10 Pertuzumab Trastuzumab Drug Combination

Deadline: 31 Dec 2026

Germany

Ref. No.: 10579947

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Open House Biologics Discount Agreements 2024 13 Somatropin

Deadline: 31 Dec 2026

Germany

Ref. No.: 10549827

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Pharmaceutical Discount Agreements Pursuant To Section 130A Paragraph 8 Of The Social Security Code Sgb V Within The Framework Of Open House Procedures

Deadline: 05 Nov 2026

Germany

Ref. No.: 10539274

EMD:Ref Document

Bid Value: Ref Document

193 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 10531330

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Medicines Containing The Active Ingredient Rituximab In The Dosage Form Concentrate For Infusion Solution Atc L01Fa01

Deadline: 31 Oct 2026

Germany

Ref. No.: 10526727

EMD:Ref Document

Bid Value: Ref Document

188 Days Left

Medicines Containing The Active Ingredient Sevelamer Hydrochloride Atc V03Ae02

Deadline: 31 Oct 2026

Germany

Ref. No.: 10506658

EMD:Ref Document

Bid Value: Ref Document

188 Days Left

Medicines Containing The Active Ingredient Combination Brinzolamide And Timolol Atc S01Ed67

Deadline: 31 Oct 2026

Germany

Ref. No.: 10504883

EMD:Ref Document

Bid Value: Ref Document

188 Days Left

Medicines Containing The Active Ingredient Bimekizumab Atc L04Ac21

Deadline: 31 Oct 2026

Germany

Ref. No.: 10497747

EMD:Ref Document

Bid Value: Ref Document

188 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 10490755

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Medicines Containing The Active Ingredient Combination Formoterol And Beclometasone Atc R03Ak08 In The Strength 200 6 Micrograms

Deadline: 31 Oct 2026

Germany

Ref. No.: 10482605

EMD:Ref Document

Bid Value: Ref Document

188 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 10471265

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 10438499

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Conclusion Of A Non Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open House Model For The Active Ingredient Brinzolamide Timolol Official Atc Code S01Ed67

Deadline: 31 Dec 2026

Germany

Ref. No.: 10433324

EMD:Ref Document

Bid Value: Ref Document

249 Days Left

Discover Tenders by Pharmaceutical Articles Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Pharmaceutical Articles Sector

Filter Your Search

FREE Trial plan for all new users!